Active Filter(s):
Details:
Under the partnership, Sage Group will assist Cadrenal in exploring strategic partnerships, co-development and licensing agreements for ATI-5923 (tecarfarin), a late-stage, novel, oral and reversible anticoagulant designed to prevent heart attacks, strokes and deaths.
Lead Product(s): Tecarfarin,Warfarin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ATI-5923
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: The Sage Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 12, 2023